Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $2.6752W HIGH $6.65
Volume
7.73 M
Value Traded
11.49 M
Short % Float
32.98%
+20.13%Week
+3.17%1 Month
-5.29%3 Month
+4.37%6 Month
-84.34%5 Year
-84.34%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
649.33 M
EPS (TTM)
-1.04
P/E Ratio
-
Ent. Value
554.26 M
Total Shares
181.38 M
Float Shares
97.44 M
Insiders
46.28%
Institutions
49.33%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PRME Catalyst Timeline
Dated clinical, regulatory and corporate events for Prime Medicine, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Prime Medicine, Inc.
236Total events
14Upcoming
31Tier-1 (high impact)
2022 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲First Patient DosedPM577aTrial
First patient dosed in global Phase 1/2 trial of PM577a for H1069Q-mutated Wilson disease
H1069Q-mutated Wilson diseasesource ↗
▲Rare Pediatric DiseasePM577Designation
FDA granted Rare Pediatric Disease designation to PM577 for Wilson disease
Wilson diseasesource ↗
●IND SubmissionPM647IND
IND and/or CTA submission for PM647 expected in 3Q 2026
Alpha-1 Antitrypsin Deficiencysource ↗
▲IP Litigation RulingPM647IP / Competition
Favorable arbitration resolution with Beam Therapeutics for PM647
Alpha-1 Antitrypsin Deficiencysource ↗
▲RMATPM359Designation
FDA granted RMAT designation for PM359
p47phox-deficient chronic granulomatous disease (CGD)source ↗
▲IND ClearancePM577aIND
New Zealand Medsafe clearance of Clinical Trial Application for PM577a
Wilson Disease (H1069Q mutation)source ↗
◆Oral PresentationPresentation
Prime Medicine CEO to present at Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Prime Medicine to present at Jefferies Global Healthcare Conference
◆IND SubmissionPM647IND
IND/CTA filing for PM647 in AATD
Alpha-1 Antitrypsin Deficiency (AATD)source ↗
▲Other Regulator MilestonePM577aEx-US Regulatory
New Zealand Medsafe cleared CTA for PM577a
Wilson diseasesource ↗
◆Oral PresentationPM577Presentation
Oral presentation at ASGCT 2026 on Wilson Disease program
Wilson Diseasesource ↗
◆Trial InitiationPM577aTrial
Initiation of Phase 1/2 clinical trial expected
Wilson Disease (H1069Q mutation)source ↗
●IND SubmissionIND
IND and/or CTA filing for AATD program
alpha-1 antitrypsin deficiency (AATD)source ↗
●IND SubmissionPM647IND
IND/CTA filing for PM647 expected in mid-2026
Alpha-1 Antitrypsin Deficiencysource ↗
◆Oral PresentationPresentation
Prime Medicine management to participate in Barclays Global Healthcare Conference
◆Oral PresentationPresentation
Prime Medicine management to participate in Leerink Partners Global Biopharma Conference
◆Oral PresentationPresentation
Prime Medicine management to participate in TD Cowen 46th Annual Health Care Conference
◆Oral PresentationPresentation
Prime Medicine corporate overview at 44th Annual J.P. Morgan Healthcare Conference
◆IND SubmissionPM577IND
IND/CTA Filing for PM577 for Wilson's Disease
Wilson's Disease (H1069Q-driven)source ↗
◆Topline ReadoutPM359Clinical Data
Initial clinical data from Phase 1/2 trial of PM359 in CGD
chronic granulomatous disease (CGD)source ↗
▲Full ResultsPM359Clinical Data
NEJM publication of Phase 1/2 clinical data for PM359 in CGD
p47phox chronic granulomatous disease (CGD)source ↗
●Poster PresentationPM359Presentation
Poster presentation at 67th ASH Annual Meeting
p47phox chronic granulomatous disease (CGD)source ↗
◆Oral PresentationPresentation
Prime Medicine CEO to present at 8th Annual Evercore Healthcare Conference
▲PublicationPM359Presentation
Phase 1/2 clinical results published in The New England Journal of Medicine
p47phox-deficient chronic granulomatous disease (CGD)source ↗
▲Full ResultsPM359Clinical Data
Publication of Phase 1/2 clinical data for PM359 in NEJM
Chronic Granulomatous Diseasesource ↗
●Poster PresentationPM359Presentation
Poster presentation at 67th ASH Annual Meeting
Chronic Granulomatous Diseasesource ↗
◆Oral PresentationPresentation
Prime Medicine CEO to present at Jefferies Global Healthcare Conference
●Poster PresentationPM577Presentation
New preclinical data for PM577 in Wilson's Disease to be presented at AASLD
Wilson's Diseasesource ↗
◆Oral PresentationPresentation
Prime Medicine management to participate in panel discussion at Cell & Gene Meeting on the Mesa
◆Oral PresentationPresentation
Prime Medicine management to participate in fireside chat at Chardan Genetic Medicines Conference
◆Oral PresentationPresentation
Morgan Stanley 23rd Annual Global Healthcare Conference fireside chat
▲Topline ReadoutPM359Clinical Data
Positive data from two patients in Phase 1/2 trial of PM359 for CGD
Chronic Granulomatous Disease (CGD)source ↗
Past FDA Catalysts and PDUFA Decisions
How PRME actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2026-09-30 | PM647 | IND Submission | IND |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F19 / 100
Pipeline Score
$1M
Pipeline Value
Richly Valued
Valuation Signal
2
Drugs Scored
0.0x
rNPV / MCap
Top 96%
Micro Cap(rank 632 of 658)
Percentile Rank
Prime Medicine, Inc. has significant pipeline risk (19/100), with 2 assets in development, but cash runway is a concern.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PM359 Monoclonal antibodyNCT06559176 | Chronic Granulomatous Disease | Phase 1 | ENROLLING BY_INVITATION | 12 | Feb 1, 2030 |
Clinical Trial Results
Readouts, endpoints and source filings for every PRME program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| PM359 Fast TrackRMATOrphan+1 | chronic granulomatous disease | Phase 1/2 | 2025-12-08 | rapid neutrophil and platelet engraftment; durable restoration of NADPH oxidase activity; early clinical benefitRead More | Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous DiseaseRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Makhni Svetlana NiOfficer (Chief Financial Officer) | Grant/Award | 800,000 800,000 held | $0.00 | 04/16/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in PRME
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Casdin Capital, LLC | 0.6 % (-25 %) | 11.69 M | 3.17 M |
PRME Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-11-20 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How PRME ranks across every disease it competes in
Competitive Position is a premium feature
See how PRME ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialPRME News
PRME▲ +7.7%on this news· ran to +20% by day 3
Prime Medicine Announces First Patient Dosed in Global Phase 1/2 Clinical Trial of PM577a for H1069Q-Mutated Wilson Disease
Prime Medicine has initiated a global Phase 1/2 clinical trial for PM577a, targeting the H1069Q mutation in Wilson disease. The trial aims to evaluate the safety and efficacy of this one-time therapy, which has received Rare Pediatric Disease designation from the FDA. Initial clinical data is expected by 2027.
Read more →PRME▼ -5.5%on this news
Prime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM647 in Alpha-1 Antitrypsin Deficiency
Prime Medicine has received FDA clearance for its Investigational New Drug application for PM647, aimed at treating Alpha-1 Antitrypsin Deficiency (AATD). This clearance allows the company to initiate a Phase 1/2 clinical trial, which will evaluate the safety and efficacy of PM647 in adults with AATD. The investigational therapy is designed to correct the underlying genetic mutation responsible for the disease, potentially offering a one-time curative treatment.
Read more →PRMEPrime Medicine to Participate in Upcoming Investor Conferences
Prime Medicine, Inc. announced its participation in three upcoming investor conferences, including the Wells Fargo 21st Annual Healthcare Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company aims to showcase its advancements in gene editing therapies and will offer live audio webcasts for investor engagement. This highlights Prime Medicine's commitment to transparency and investor relations.
Read more →PRMEPrime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine reported its Q2 2026 financial results, highlighting significant advancements in its clinical programs. The company received clearances for its PM577a program in Wilson disease and secured rights for PM647 in Alpha-1 Antitrypsin Deficiency following a favorable arbitration. Additionally, PM359 received RMAT designation from the FDA, aiding its path toward a BLA submission. The company maintains a strong cash position, ensuring operational funding into 2027.
Read more →PRMEPrime Medicine Announces U.S. FDA Clearance of Investigational New Drug Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine has received FDA clearance for its Investigational New Drug application for PM577a, aimed at treating H1069Q-mutated Wilson disease. This clearance, alongside a previously approved clinical trial in New Zealand, establishes a global Phase 1/2 clinical program. The trial will evaluate the safety and efficacy of PM577a, with initial data expected in 2027.
Read more →PRME▲ +15.8%on this news
Prime Medicine Announces Positive Resolution to Arbitration with Beam Therapeutics
Prime Medicine has received a favorable ruling from an arbitration tribunal, which confirmed its rights to develop and commercialize PM647 for AATD. The tribunal also ruled that Prime Medicine does not owe any monetary damages to Beam Therapeutics. The company is now preparing to submit an IND and/or CTA filing for PM647.
Read more →PRMEPrime Medicine Receives U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for PM359 for the Treatment of Chronic Granulomatous Disease (CGD)
Prime Medicine has been granted RMAT designation by the FDA for PM359, an investigational therapy for chronic granulomatous disease (CGD). This designation is based on promising Phase 1/2 clinical data, which indicates PM359's potential to significantly improve patient outcomes. The therapy is designed to address a critical unmet need in CGD, where treatment options are limited.
Read more →PRMEPrime Medicine Announces New Zealand Clearance of Clinical Trial Application for PM577a in H1069Q-mutated Wilson Disease
Prime Medicine has received clearance from New Zealand's Medsafe for its Clinical Trial Application for PM577a, targeting the H1069Q mutation in Wilson Disease. This marks the first clinical authorization for an in vivo Prime Editing therapy. The Phase 1/2 trial is set to begin in late 2026, with initial data expected in 2027, aiming to provide a one-time curative option for patients.
Read more →PRMEPrime Medicine to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Prime Medicine, Inc. will have its CEO, Dr. Allan Reine, participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The event will be held in Miami Beach, FL, and will be accessible via a live audio webcast. Prime Medicine focuses on developing one-time curative genetic therapies using its proprietary Prime Editing platform.
Read more →PRMEPrime Medicine to Present at Jefferies Global Healthcare Conference
Prime Medicine, Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026. The CEO, Allan Reine, will participate in a fireside chat that will be accessible via a live audio webcast. Prime Medicine focuses on one-time curative genetic therapies developed through its Prime Editing platform, aiming to address various genetic mutations and diseases. The company has a diversified portfolio targeting liver, lung, immunology, and oncology conditions, with plans for future expansions into additional therapeutic areas.
Read more →PRME▼ -8.7%on this news
Prime Medicine Reports First Quarter 2026 Financial Results and Provides Business Updates
Prime Medicine, Inc. reported its financial results for Q1 2026, highlighting progress in its gene editing pipeline. The company is on track to file regulatory applications for PM577 and PM647, with initial clinical data expected in 2027. Despite a net loss of $49.1 million, Prime Medicine remains focused on advancing its therapies and has strengthened its leadership team.
Read more →PRMEPrime Medicine Appoints Svetlana Makhni as Chief Financial Officer
Prime Medicine has appointed Svetlana Makhni as Chief Financial Officer, effective immediately. Makhni will manage the company's financial operations and strategy, leveraging her extensive experience in biotechnology and investment banking. The CEO expressed confidence in her ability to position the company for success as it advances its therapeutic programs for Wilson Disease and Alpha-1 Antitrypsin Deficiency.
Read more →PRME▼ -9.2%on this news
Prime Medicine Reports Full Year 2025 Financial Results and Provides Business Updates
Prime Medicine reported its financial results for 2025, highlighting a strong cash position of $191 million and plans to file IND and CTA for Wilson Disease and AATD programs in 2026. The company is also progressing towards submitting a BLA for PM359 following positive clinical data. Despite an increased net loss and R&D expenses, Prime Medicine remains focused on advancing its gene editing platform and delivering transformative therapies.
Read more →PRME▲ +9.2%on this news
Prime Medicine to Present at 44th Annual J.P. Morgan Healthcare Conference
Prime Medicine, Inc. will present a corporate overview at the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. CEO Allan Reine will discuss the company's advancements in gene editing therapies, particularly its proprietary Prime Editing platform. The presentation will be available via a live audio webcast, with a replay accessible for 90 days post-event.
Read more →PRME▲ +12.6%on this news
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
Prime Medicine announced the publication of Phase 1/2 clinical data for PM359, an investigational treatment for chronic granulomatous disease (CGD), in the New England Journal of Medicine. The data showed promising results in two patients, including rapid engraftment and restoration of activity. The findings support the potential of Prime Editing as a safe and effective therapy for CGD.
Read more →PRMEPrime Medicine to Present at 8th Annual Evercore Healthcare Conference
Prime Medicine, Inc. will present at the 8th Annual Evercore Healthcare Conference on December 2, 2025. CEO Allan Reine will participate in a fireside chat, focusing on the company’s advancements in gene editing therapies. Prime Medicine is utilizing its proprietary Prime Editing platform to develop innovative one-time curative genetic therapies, targeting a range of diseases across liver, lung, immunology, and oncology. The conference presentation highlights the company's commitment to advancing its research and development in genetic therapies.
Read more →PRMECORRECTION - Prime Medicine Reports Third Quarter 2025 Financial Results and Provides Business Updates
Prime Medicine reported its third quarter 2025 financial results, highlighting advancements in its pipeline, including new preclinical data for PM577 in Wilson's Disease and the nomination of PM647 for Alpha-1 Antitrypsin Deficiency. The company plans to file INDs for both programs in 2026, with initial clinical data expected in 2027. Additionally, Matthew Hawryluk has been appointed as Chief Business Officer to strengthen the leadership team.
Read more →About Prime Medicine, Inc.
Headquarters60 FIRST ST., CAMBRIDGE, MA, 02141
BIOPHARMAWATCH ELITE PLUS
Trade the next PRME catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime